Literature DB >> 15378856

Immunomodulatory effect of shikonin derivatives isolated from Lithospermum canescens on cellular and humoral immunity in Balb/c mice.

A Pietrosiuk1, E Skopińska-Rózewska, M Furmanowa, H Wiedenfeld, E Sommer, I Sokolnicka, E Rogala, D Radomska-Leśniewska, J Bany, M Malinowski.   

Abstract

The immunomodulatory activity of acetylshikonin (ACS) and isobutyrylshikonin (IBS) was studied in female and male inbred Balb/c mice, and in F1 hybrids (Balb/c x C3H). ACS and IBS were isolated from Lithospermum canescens Lehm. (Boraginaceae) roots. Splenocytes from mice fed 40 microg of ACS had higher proliferative potential in cultures with PHA than corresponding controls and also higher migratory in vitro activity than splenocytes obtained from control animals. ACS at a 40 microg daily dose stimulated G-v-H reaction but inhibited it at a 200 microg dose. IBS at a 40 microg dose significantly increased humoral response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378856

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  11 in total

1.  The shikonin derivatives and pyrrolizidine alkaloids in hairy root cultures of Lithospermum canescens (Michx.) Lehm.

Authors:  A Pietrosiuk; K Sykłowska-Baranek; H Wiedenfeld; R Wolinowska; M Furmanowa; E Jaroszyk
Journal:  Plant Cell Rep       Date:  2006-05-03       Impact factor: 4.570

2.  Dual role of shikonin in early and late stages of collagen type II arthritis.

Authors:  Qiaomei Dai; Jianghong Fang; Feng-shan Zhang
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

3.  Acute and 28-Day Subacute Toxicity Studies of Hexane Extracts of the Roots of Lithospermum erythrorhizon in Sprague-Dawley Rats.

Authors:  Chung-Tack Han; Myoung-Jun Kim; Seol-Hee Moon; Yu-Rim Jeon; Jae-Sik Hwang; Chunja Nam; Chong-Woo Park; Sun-Ho Lee; Jae-Bum Na; Chan-Sung Park; Hee-Won Park; Jung-Min Lee; Ho-Song Jang; Sun-Hee Park; Kyoung-Goo Han; Young Whan Choi; Hye-Yeong Lee; Jong-Koo Kang
Journal:  Toxicol Res       Date:  2015-12

4.  Shikonin Prolongs Allograft Survival via Induction of CD4+FoxP3+ Regulatory T Cells.

Authors:  Qiaohuang Zeng; Feifei Qiu; Yuchao Chen; Cuihua Liu; Huazhen Liu; Chun-Ling Liang; Qunfang Zhang; Zhenhua Dai
Journal:  Front Immunol       Date:  2019-04-01       Impact factor: 7.561

5.  Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo.

Authors:  Hongmei Xia; Chengyi Tang; Heng Gui; Xiaoming Wang; Jinliang Qi; Xiuqiang Wang; Yonghua Yang
Journal:  Biosci Rep       Date:  2013-02-01       Impact factor: 3.840

6.  Effect of l-phenylalanine on PAL activity and production of naphthoquinone pigments in suspension cultures of Arnebia euchroma (Royle) Johnst.

Authors:  Katarzyna Sykłowska-Baranek; Agnieszka Pietrosiuk; Marcin R Naliwajski; Anna Kawiak; Małgorzata Jeziorek; Sylwia Wyderska; Ewa Lojkowska; Ioanna Chinou
Journal:  In Vitro Cell Dev Biol Plant       Date:  2012-06-21       Impact factor: 2.252

7.  Shikonin reduces endometriosis by inhibiting RANTES secretion and mononuclear macrophage chemotaxis.

Authors:  Dong-Ping Yuan; Lin Gu; Jun Long; Jie Chen; Jie Ni; Ning Qian; Ying-Li Shi
Journal:  Exp Ther Med       Date:  2013-12-23       Impact factor: 2.447

8.  Shikonin Promotes Skin Cell Proliferation and Inhibits Nuclear Factor-κB Translocation via Proteasome Inhibition In Vitro.

Authors:  Yan Yan; Minao Furumura; Takako Gouya; Atsufumi Iwanaga; Kwesi Teye; Sanae Numata; Tadashi Karashima; Xiao-Guang Li; Takashi Hashimoto
Journal:  Chin Med J (Engl)       Date:  2015-08-20       Impact factor: 2.628

9.  Shikonin Inhibits Inflammatory Response in Rheumatoid Arthritis Synovial Fibroblasts via lncRNA-NR024118.

Authors:  Ke-Ya Yang; Dong-Liang Chen
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-10       Impact factor: 2.629

10.  Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression.

Authors:  Qiaomei Dai; Ji Li; Yu Yun; Jianwei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.